Amarin Corporation
Could not find a ticker for this position, may be a filing error
A Dublin-based biopharmaceutical company that makes Vascepa (sold as Vazkepa in Europe), a prescription-grade, ultra-pure omega-3 medicine from fish oil that doctors give to patients with high triglycerides to lower heart-attack and stroke risk. It began life in 1989 as Ethical Holdings plc, a neuroscience firm, before rebranding as Amarin in 1999 and pivoting to heart health. A fun twist: its drug is a highly purified form of EPA, the same fatty acid in everyday fish-oil capsules — but this one is a single-molecule prescription drug, not a dietary supplement.
3.50% Exchangeable Senior Notes due 2032 issued by Corsicanto Limited
No financial data available for this security.